-+ 0.00%
-+ 0.00%
-+ 0.00%

Oculis plans Q4 2026 IND filing to launch Privosegtor trial in acute MS relapses after FDA pre-IND feedback

PUBT·08/03/2026 08:00:46
Listen to the news
Oculis plans Q4 2026 IND filing to launch Privosegtor trial in acute MS relapses after FDA pre-IND feedback
  • Oculis received FDA pre-IND feedback backing its Privosegtor program for acute multiple sclerosis relapses.
  • Results from the earlier Phase 2 ACUITY study have already been presented, showing neuroprotective benefits in optic neuritis without detailing metrics.
  • The FDA supported using existing Privosegtor data for a new IND, lowering development friction for the expansion into MS relapses.
  • An IND filing for acute MS relapses is planned for Q4 2026, setting up a new clinical trial pathway beyond optic neuritis.
  • Additional updates on the program are slated for a virtual R&D Day in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030400OMX_____CNEWS_EN_GNW1001255670_en) on August 03, 2026, and is solely responsible for the information contained therein.